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Autism spectrum disorder (ASD) is appropriately named due to
the broad variability or clinical heterogeneity, which in turn is
linked to genetic heterogeneity. Such clinical heterogeneity is dif-
ficult to understand and difficult to treat under the auspices of a
single disorder. The logical approach to this problem is to try to
reduce the heterogeneity by stratifying ASD patients into smaller
more homogeneous subgroups. However, this task is difficult as
the stratification of ASD on the basis of behavioral differences
would require clinicians to make evermore “new” categories of
behavioral disorders when the core neurobiological deficits may
be the same or similar. This difficulty is further amplified when
the extreme genetic heterogeneity associated with ASD is consid-
ered and where some comparable genetic lesions are associated
with different behavioral profiles and in some cases with differ-
ent neuropsychiatric conditions. This Research Topic of Frontiers
addresses these problems from a diversity of perspectives with the
aim of clarifying these issues and promoting novel solutions.
The review by Eapen et al. (2013) sets the tone for this Research
Topic of Frontiers by putting clinical heterogeneity in perspective
with ASD genotypes, phenotypes, and potentially corresponding
treatment outcomes necessitating the need to search for useful
endophenotypes to help improve early intervention. The authors
provide a perspective to the continuum of genetic variants (rare
and common) present within the general population that has the
potential to impact social-cognition and behavior. This also pro-
vides the ideal introduction to the genome-wide association study
reported by Jones et al. (2013) that identified two ASD candi-
date genes (PRKCB1 and CBLN1) from the general population
with nominal association to autistic-like traits. PRKCB1 (the gene
encoding Protein kinase C-B1 involved in signal transduction and
the regulation of gene expression) has been reported previously in
linkage and association studies for ASD; while CBLN1 is just one
of the many ligands for the neurexins – neuronal cell adhesion
molecules involved in synaptogenesis and neural circuitry.
Neurexin mutations are common in ASD and all of the
gene families encoding neurexin trans-synaptic ligands have been
implicated previously in ASD. Together, the neurexins (NRXNs
1–4) and their different trans-synaptic ligands (CBLNs/GRIDs,
LRRTMs, and NLGNs) are referred to collectively as the neurexin
trans-synaptic connexus (NTSC). Here, Clarke and Eapen (2014)
review the NTSC in detail as the basis for the molecular stratifi-
cation of ASD. As common as NTSC mutations are in ASD, they
are even more common in Tourette syndrome including recur-
rent disruptions of the intergenic region around the CBLN2 gene.
NTSC mutations are also found in patients with Schizophrenia and
intellectual disability. As such, Clarke et al. argue that the NTSC
should represent the primary determinate for the molecular strat-
ification of ASD and related neurodevelopmental disorders, from
where characterization of the genetic architecture should provide a
window for understanding how the NTSC and secondary variants
function to specify behavior.
Recapitulating ASD models in rodents for mutations like those
within the NTSC provide probably the best approach for improv-
ing drug development for ASD. The study by Argyropoulos et al.
(2013) takes this one step further by describing the use of rodent
models to identify and characterize endophenotypes that might
be useful for the stratification of ASD patients as indicators of the
biological pathways affected. This bottom-up approach is taken
further by Unwin et al. (2013) in their study that suggests that
the risk factors of “low birth weight” and “in utero exposure” to
selective serotonin reuptake inhibitors give rise to some of the
novel endophenotypes such as “sleep disturbance” in the pregnant
mother and “gastrointestinal complaints in children with ASD”
that could be useful for stratifying patients on the basis of cause
and effect. Further, Billeci et al. (2013) have reviewed the use of
advanced EEG techniques that has the potential to find distinctive
patterns of abnormalities in ASD subjects, paving the way for the
development of tailored intervention strategies. Similarly, the use
of neuroimaging techniques to explore the heterogeneity in ASD
is the focus of the review by Lenroot and Yeung (2013).
It appears that the phenotypic variability within ASD and the
phenotypic overlap between ASD and other neurodevelopmental
disorders such as Tourette syndrome, attention deficit hyperactiv-
ity disorder (ADHD), schizophrenia, language disorder, and intel-
lectual disability could be due to the fact that the genes converge
toward a core set of dysregulated biological processes that affect
distinct neurodevelopmental pathways involved in synapse devel-
opment/maintenance and circuitry formation through effects on
neurogenesis, axon guidance in dendritic projections, and/or neu-
ronal migration. Thus, defects in synaptic development can result
in abnormal development across disorders and broad domains
but yet carry distinct neurocognitive and behavioral profiles. The
penetrance of the different comorbidities may in turn be related
to the dose effects of gene abnormality or the timing of events
when different neuronal regions and circuitry are being formed, as
may be the influence of gender, intrauterine and perinatal events,
epigenetics, and other environmental modulators. In this regard,
accumulating evidence supports the notion that immune cells
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play important roles in normal brain function, outside of neu-
roinflammation. Voineagu and Eapen (2013) have reviewed recent
data demonstrating the involvement of synaptic dysfunction and
abnormal immune responses in ASD, and in particular the role
of microglia in synaptic pruning during postnatal brain develop-
ment, a period that coincides with the onset of ASD symptoms.
Given the multi modal and diverse origins of ASD, including
the genetic as well as environmental modulation in the etiol-
ogy, therapeutic interventions should also reflect such diversity.
Furthermore, it seems that genetically mediated deficits and conse-
quent functional impairments involve activity-dependent synapse
development that depends on postnatal learning and experi-
ence. In this regard, the paper by Vivanti et al. (2013) suggests
that intellectual disability in ASD might emerge as a conse-
quence of severe social-communication deficits on the experience-
dependent mechanisms underlying neurocognitive development.
Such a model would predict that early intervention will prevent
or reduce the risk of these deficits cascading into a trajectory
toward full expression of the disorder by exploiting the neuronal
maturation and brain plasticity. Thus, identifying homogeneous
subgroups within ASD and matching appropriate interventions
remain the key challenge for future research.
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